Document is current
Any future updates will be listed below
-
Authors
Mars, Sarah
Ondocsin, Jeff
Holm, Nicole
Ciccarone, Daniel
-
Funding
Funding for this research was provided by:
National Institute on Drug Abuse (DA037820, DA037820, DA054190, DA037820)
- License Information
-
More Information
Article History
Received: 22 May 2023
Accepted: 27 February 2024
First Online: 5 March 2024
Declarations
:
: Dr. Daniel Ciccarone reports the following relevant financial relationships during the past 12 months: 1, he is a scientific advisor to Celero Systems and 2, he has been retained as an expert witness in ongoing prescription opioid litigation by Motley Rice, LLP. The remaining authors have no relevant financial or non-financial interests to disclose.
: Ethics approval for the study protocol was given by the Committee on Human Research at the University of California, San Francisco in accordance with the Declaration of Helsinki.
: Informed consent was obtained from all individual participants included in the study and, where quotations have been used, for these to be published in a journal article.
